Physician profile
Seth J Page
NPI 1518974948
$18,188.94
in general payments reported to CMS, 2019-2025
79 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,147 · 2020: $3,226 · 2021: $4,286 · 2022: $2,480 · 2023: $1,883 · 2024: $1,787 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,954 · Education: $97.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,954.00 |
| Education | $97.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,651.60 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,386.54 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $1,322.77 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,022.96 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $845.55 | 2019-2025 | Enhertu, Imfinzi |
| Amgen INC. | $843.10 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Merck Sharp & Dohme LLC | $648.83 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Celgene Corporation | $583.17 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $553.48 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Verity Pharmaceuticals INC. | $500.00 | 2021 | |
| Janssen Biotech, INC. | $460.38 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Abbvie INC. | $442.76 | 2019-2025 | |
| Array Biopharma INC | $408.79 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Daiichi Sankyo INC. | $401.96 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $375.80 | 2019-2025 | Phesgo, Itovebi, Tecentriq |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.